Humacyte

HUMA · Nasdaq · United States

Share price · HUMA

$0.50-0.08 (-14.05%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.9M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HUMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+29.6%
  2. 15 Oct 2026+24.1%
  3. 9 Oct 2026-9.3%
  4. 19 Aug 2026+26.3%
  5. 13 Aug 2026-17.3%
  6. 23 Jun 2026-16.5%

    Nothing announced by HUMA that day or the session before.

  7. 11 Jun 2026-19.4%
  8. 13 May 2026+24.2%
  9. 7 May 2026+9.8%

    Nothing announced by HUMA that day or the session before.

  10. 27 Apr 2026+15.1%

Share of unusual movement by asset

For each asset, the share of HUMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Human Acellular Vessel (Humacyte)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—59%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
tissue-engineered acellular vascular graftOther
Atherosclerotic Cardiovascular DiseaseVascular TraumaHemodialysis Access

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Human Acellular Vessel (Humacyte)Phase 3End Stage Renal Disease (ESRD)
Est. primary completion 2027-06 · NCT05908084 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Human Acellular Vessel (Humacyte)Phase 3Vascular Trauma, Arterial Injury, Arterial Bleeding
Est. primary completion 2028-12 · NCT07762313 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.0M$14M$65M$16M-$15M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.4M$18M$80M$37M-$22M operating cash flowreport ↗
2026-Q1$0.5M$19M$49M$18M-$25M operating cash flowreport ↗
2025-Q3$0.8M$17M$20M$18M-$24M operating cash flowreport ↗
2025-Q2$0.3M$22M$88M$38M-$26M operating cash flowreport ↗
2025-Q1$0.5M$15M$113M—-$29M operating cash flowreport ↗
2024-Q3$0$23M$71M$39M-$23M operating cash flowreport ↗
2024-Q2$0$24M$94M$57M-$21M operating cash flowreport ↗
2024-Q1$0$21M$116M$32M-$27M operating cash flowreport ↗
2023-Q3—$19M$100M+ $0 short-term inv.$26M-$13M operating cash flowreport ↗
2023-Q2—$21M$115M+ $0 short-term inv.$23M-$23M operating cash flowreport ↗
2023-Q1—$17M$130M+ $2.1M short-term inv.$37M-$19M operating cash flowreport ↗
2022-Q3—$17M$164M+ $8.0M short-term inv.$25M-$17M operating cash flowreport ↗
2022-Q2—$15M$181M+ $8.0M short-term inv.—-$17M operating cash flowreport ↗
2022-Q1—$16M$198M+ $8.0M short-term inv.$20M-$19M operating cash flowreport ↗
2021-Q3—$15M$240M$32M-$59M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.0M$69M$51M$10M-$105M operating cash flowreport ↗

Humacyte reported FY2025 revenue of $2.04M, compared with $0M in the prior year. R&D spend was $69.3M, down 21.8% YoY. The company ended the period with $50.85M in cash and equivalents, and reported a net loss of $40.83M, equating to a quarterly net burn of $40.83M.

Operationally, Humacyte continued commercializing Symvess, its FDA-approved acellular tissue engineered vessel for extremity vascular trauma, following the December 2024 approval and 2025 U.S. launch. In dialysis access, the V007 Phase 3 trial met co-primary endpoints, with V012 interim results planned for 2Q26 and a supplemental BLA expected in the second half of 2026. The company also plans a first-in-human CTEV study for coronary bypass in the second half of 2026 and continued preclinical work on the BioVascular Pancreas, with first-in-human studies planned for 2027. Manufacturing capacity is expected to exceed 40,000 ATEVs annually at its existing facility.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$89M$95M$37M-$98M operating cash flowreport ↗
2023-FY—$77M$81M+ $0 short-term inv.$28M-$73M operating cash flowreport ↗
2022-FY—$63M$150M+ $2.1M short-term inv.$3.0M-$71M operating cash flowreport ↗
2021-FY—$61M$218M+ $8.0M short-term inv.$6.6M-$81M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($90K), 2 sales ($82K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-06COWARD D SCOTT · directorAward / grant (derivative)125,000——Form 4
2026-10-06Kuznik Paul Brian · directorAward / grant (derivative)125,000——Form 4
2026-09-14Jones Keith Anthony · directorOpen-market purchase10,000$0.56$6KForm 4
2026-08-20Jones Keith Anthony · directorOpen-market purchase10,000$0.69$7KForm 4
2026-08-17Jones Keith Anthony · directorOpen-market purchase30,000$0.59$18KForm 4
2026-06-11Dougan Brady W · directorAward / grant (derivative)0——Form 4
2026-06-11Brown Emery N. · directorAward / grant (derivative)80,000——Form 4
2026-06-11Bamforth John Philip · directorAward / grant (derivative)80,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 157 reporting institutions held 59.0M shares ($35.6M, 21.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.12,316,955$7.5M
2VANGUARD CAPITAL MANAGEMENT LLC7,158,162$4.3M
3ANTIPODES PARTNERS Ltd5,723,750$3.5M
4GREAT POINT PARTNERS LLC3,750,000$2.3M
5GEODE CAPITAL MANAGEMENT, LLC3,658,108$2.2M
6STATE STREET CORP3,043,929$1.8M
7UBS Group AG2,782,070$1.7M
8Woodline Partners LP2,002,582$1.2M
9AQR CAPITAL MANAGEMENT LLC1,924,691$1.2M
10VANGUARD PORTFOLIO MANAGEMENT LLC1,417,825$861K
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,291,345$783K
12NORTHERN TRUST CORP1,223,908$743K
13SUSQUEHANNA INTERNATIONAL GROUP, LLP1,058,048$642K
14VANGUARD FIDUCIARY TRUST CO1,011,029$614K
15LPL Financial LLC864,463$524K